Skip to main content

Table 1 Basic characteristics of cervical cancer cases and cancer-free controls

From: Mitochondrial DNA copy number in cervical exfoliated cells and risk of cervical cancer among HPV-positive women

Variables Cases (n = 591) Controls (n = 373) P
N (%) N (%)
Age, years    0.36 e
 < 50 339(57.36) 226(60.59)  
 ≥ 50 252(42.64) 147(39.41)  
HPV16    < 0.001e
 Negative 268(45.35) 300(80.43)  
 Positive 323(54.65) 73(19.57)  
HPV18    0.43 e
 Negative 532(90.02) 342(91.69)  
 Positive 59(9.98) 31(8.31)  
HPV52    < 0.001e
 Negative 488(82.57) 272(72.92)  
 Positive 103(17.43) 101(27.08)  
HPV58    0.005e
 Negative 536(90.69) 315(84.45)  
 Positive 55(9.31) 58(15.55)  
Other type a    < 0.001e
 Negative 481(81.39) 239(64.08)  
 Positive 110(18.61) 134(35.92)  
Multiple infection    0.15e
 Negative 538(91.03) 350(93.83)  
 Positive 53(8.97) 23(6.17)  
Grade b
 High 27(7.99)   
 Middle 178(52.66)   
 Low 133(39.35)   
Histology c
 Squamous 536(94.87)   
 Adeno/adenosquamous 29(5.13)   
FIGO d
 I/II 366(83.75)   
 III/IV 71(16.25)   
 mtCN (median, quartile) 1.63(0.59–3.43) 1.23(0.53–2.76) 0.03f
  1. Bold values indicate P < 0.05
  2. Abbreviation: HPV human papillomavirus, FIGO International Federation of Gynecology and Obstetrics, mtCN mitochondrial DNA copy number
  3. aOthers include HPV31, 33, 35, 39, 45, 51, 56, 59, 66, and 68
  4. bGrade information was available in 338 cervical cancer cases
  5. cHistological information was available in 565 cases
  6. dFIGO information was available in 437 cervical cancer cases
  7. eDerived from χ2 test
  8. fDerived from Wilcoxon rank-sum test